Developing unique and non-invasive blood tests for liver cancers and fibrosis-cirrhosis
Proprietary biomarkers and assays based on glycoproteins with sugars that are abnormally altered in liver disease.
Algorithm-driven biomarker panels that use standard blood samples to measure likelihood of liver disease.
Early detection of curable liver cancer and other liver diseases to improve patient outcomes.